Howard Wang
Partner
Howard Wang focuses on patent litigation, opinion and counseling related to pharmaceutical, life sciences, medical device and chemical fields, particularly in Hatch-Waxman matters. Over the past 20 years, Mr. Wang has represented numerous corporate clients, including those based in U.S., India and China, in complex patent litigations, particularly Hatch-Waxman and ANDA litigations, and obtained favorable judgments or settlements. He has handled patent disputes involving a broad range of pharmaceutical subject matters, including drug compound, composition, formulation, process, polymorph, impurity, pharmacokinetics, administration and method of use. Mr. Wang also frequently provides legal opinions and counseling on legal and patent issues and strategies in connection with product development, regulatory filing, commercialization and business transactions, including patent licensing.
Mr. Wang is admitted to the bars of New Jersey and New York and the U.S. federal courts, including U.S. Court of Appeals for the Federal Circuit. He is a registered patent attorney before the U.S. Patent and Trademark Office (USPTO). Mr. Wang graduated cum laude and received his J.D. from the University of Illinois College of Law and was a member of the Law Review.
Mr. Wang’s legal practice is strengthened by his substantial scientific background and extensive experience in chemistry and pharmaceutical industry. Prior to his legal career, he obtained a BS degree in Chemistry from the University of Science and Technology of China (USTC) and a MS degree in Organic Chemistry from University of Pittsburgh and studied as a PhD candidate at Yale University. He also worked in process research and development in a major international pharmaceutical company and was a co-inventor of a U.S. patent and co-author of a number of scientific publications. Mr. Wang has been an invited speaker on U.S. patent law and Hatch-Waxman litigation in conferences in the U.S. and China. He is fluent in Mandarin and Cantonese Chinese.
Selected Experience
- Ferring Pharma. et al. v. Jiangsu Hansoh Pharma., D. Del. 2022, obtained settlement in suit on six Orange Book and process patents related to a polypeptide anti-cancer drug Firmagon® (degarelix))
- Abbvie v. Prinston Pharma. et al., D. Del. 2023, obtained settlement in suit on multiple Orange Book patents related to pain management drug Orilissa® (elagolix)
- UCB, Inc. et al. v. Sunshine Lake Pharma Co., Ltd., D. Del. 2020, obtained settlement in suit on patents related to epilepsy drug Briviact® (brivaracetam)
- Bial – Portela & CA S.A., et al. v. Dr. Reddy’s Labs., Ltd. et al., D. Del. 2018, obtained settlement in suit on ten patents related to epilepsy drug Aptiom® (eslicarbazepine))
- Celgene Corp. v. Sandoz Inc., et al., D.N.J., 2018, obtained settlement in suit on multiple patents related to Otezla® (apremilast) for psoriasis/psoriatic arthritis
- Forest Labs. v. Prinston Pharma. et al., D.N.J. 2017, obtained settlement in suit on patents related to anti-depression drug Fetzima® (levomilnacipran)
- Mitsubishi Tanabe Pharma Corp. et al. v. Aurobindo Pharma USA, Inc. et al., D.N.J., 2017, obtained settlement in suit on two patents related to Invokana® (canagliflozin), a drug for diabetes and other diseases
- Takeda GMBH et al. v. Strides Pharma, Inc. et al., D.N.J., 2015, obtained settlement in suit on six patents related to Daliresp® (roflumilast), an anti-inflammatory drug for lung diseases
- Helsinn Healthcare, S.A. et al. v. Dr. Reddy’s Labs., Ltd. et al., D.N.J., 2011, obtained post-trial settlement in suit on multiple Orange Book patents against client’s 505(j) and 505(b)(2) products of Aloxi® (palonosetron), an anti-nausea and vomiting injectable drug
- Pfizer, Inc. et al. v. Dr. Reddy’s Labs., Ltd. et al., D. Del., 2009, obtained dismissal and settlement after summary judgment motion in suit on an Orange Book patent directed to crystalline forms of atorvastatin (Lipitor®), a blockbuster cholesterol drug
- Stat Medical Devices, Inc. v. Gluco Perfect, L.L.C., S.D. Fla., 2007, obtained dismissal of suit after summary judgment motion for distributor and manufacturer on two patents directed to lancet devices
Invited Speaking Events
- April 23, 2008, “U.S. Pharmaceutical Patent Law and Generic Drug Patent Litigation,” Drug R&D, Regulatory and Legal Development Conference, Taibei, China
- November 26, 2018, “Overview of Generic Drug Patent Litigation in U.S.,” SAPA Biological and Pharmaceutical Development Forum, Taizhou, China
- October 21, 2019, “U.S. Generic Drug Patent Litigation,” Symposium organized by CNMPA’s Institute of Executive Development, Nanjing, China
- August 4, 2020, “U.S. Hatch-Waxman Act and Paragraph IV Patent Litigation,” Webinar
- October 11, 2023, “U.S. ANDA & 505(b)(2) Patent Litigation Strategy and Practice,” Webinar
- November 18, 2025, “U.S. ANDA & 505(b)(2) Patent Litigation Strategy,” IPLink Webinar
Memberships
- American Bar Association
- American Intellectual Property Law Association
- American Chemical Society
- Sino-American Pharmaceutical Professionals Association



中文
English